1. Home
  2. Advocacy
  3. Latest News and Practice Data
  4. Common Questions Answered About the CAP’s Amicus Brief on LDTs

Common Questions Answered About the CAP’s Amicus Brief on LDTs

Our laboratory-developed test (LDT) oversight FAQ webpage now includes commonly asked and answered questions about the CAP’s amicus brief court filing from October 7.

In the amicus brief, the CAP urged a US Federal District Court to vacate the FDA regulation for several reasons, including the ultimate impact on patient access to these critically important diagnostic tests and the FDA failing to adequately justify the rule’s unsustainable costs that will hinder the development of LDTs.

Most Recent Content

  1. Molecular Biomarkers in Salivary Gland Neoplasms
  2. March 4, 2025
  3. Advocacy News: Now Also Available on LinkedIn
  4. Register for the CAP's Fourth LDT Webinar by March 20
  5. Register for HOD/PLS 2025
  6. View All